Scinai Immunotherapeutics Ltd. (SCNI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
JERUSALEM BIOPARK, 2ND FLOOR JERUSALEM, 00000 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | ||||
| Cash and cash equivalent | ||||
| Restricted cash and investments | ||||
| Prepaid expense | ||||
| Total current assets: | ||||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | ||||
| Property, plant and equipment | ||||
| Total noncurrent assets: | ||||
| TOTAL ASSETS: | ||||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | ||||
| Accounts payable | ||||
| Other undisclosed current liabilities | ||||
| Total current liabilities: | ||||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | ||||
| Long-term debt, excluding current maturities | ||||
| Liabilities, other than long-term debt | ||||
| Operating lease, liability | ||||
| Other undisclosed noncurrent liabilities | ||||
| Total noncurrent liabilities: | ||||
| Total liabilities: | ||||
| Equity | ||||
| Equity, attributable to parent | ||||
| Additional paid in capital | ||||
| Accumulated other comprehensive loss | ||||
| Accumulated deficit | ||||
| Total equity: | ||||
| TOTAL LIABILITIES AND EQUITY: | ||||
Income Statement (P&L) (USD)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|
| Operating expenses | |||
| Operating loss: | |||
| Nonoperating expense | |||
| Net loss available to common stockholders, diluted: | |||
Comprehensive Income (USD)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|
| Net loss: | |||
| Other comprehensive income | |||
| Comprehensive loss, net of tax, attributable to parent: | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.